Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany's Merck Scraps MS Drug Cladribine After Regulators' Rebuff

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck KGaA ends development of oral cladribine tablets following rejection by European and U.S. regulators.

You may also be interested in...



Diversification Fails To Protect Merck KGaA From Industry Pressures

Merck KGaA plans to cut headcount and reduce costs, although employees are to be asked first to identify pragmatic cost-saving strategies.

Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market

FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.

Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review

The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.

Related Content

Topics

UsernamePublicRestriction

Register

PS072404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel